Transforming growth factor-β1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells
Open Access
- 25 May 2015
- journal article
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 36 (1), 113-122
- https://doi.org/10.3892/ijmm.2015.2222
Abstract
Epithelial-mesenchymal transition (EMT), a process closely related to tumor development, is regulated by a variety of signaling pathways and growth factors, such as transforming growth factor-β1 (TGF-β1) and epidermal growth factor (EGF). Hyaluronan (HA) has been shown to induce EMT through either TGF-β1 or EGF signaling and to be a regulator of the crosstalk between these two pathways in fibroblasts. In this study, in order to clarify whether HA has the same effect in tumor cells, we utilized the lung cancer cell line, A549, and the breast cancer cell line, MCF-7, and found that the effects of stimulation with TGF-β1 were more potent than those of EGF in regulating the expression of EMT-associated proteins and in enhancing cell migration and invasion. In addition, we observed that TGF-β1 activated EGF receptor (EGFR) and its downstream AKT and extracellular signal-regulated kinase (ERK) pathways. Furthermore, we found that TGF-β1 upregulated the expression of hyaluronan synthases (HAS1, HAS2 and HAS3) and promoted the expression of CD44, a cell surface receptor for HA, which interacts with EGFR, resulting in the activation of the downstream AKT and ERK pathways. Conversely, treatment with 4-methylumbelliferone (4-MU; an inhibitor of HAS) prior to stimulation with TGF-β1, inhibited the expression of CD44 and EGFR, abolished the interaction between CD44 and EGFR. Furthermore, the use of shRNA targeting CD44 impaired the expression of EGFR, deactivated the AKT and ERK pathways, reversed EMT and decreased the migration and invasion ability of cells. In conclusion, our data demonstrate that TGF-β1 induces EMT by the transactivation of EGF signaling through HA/CD44 in lung and breast cancer cells.Keywords
This publication has 37 references indexed in Scilit:
- Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFRInternational Journal of Cancer, 2014
- CD147, CD44, and the Epidermal Growth Factor Receptor (EGFR) Signaling Pathway Cooperate to Regulate Breast Epithelial Cell InvasivenessPublished by Elsevier BV ,2013
- EMT-Induced Stemness and Tumorigenicity Are Fueled by the EGFR/Ras PathwayPLOS ONE, 2013
- Cancer Stem–like Cell Marker CD44 Promotes Bone Metastases by Enhancing Tumorigenicity, Cell Motility, and Hyaluronan ProductionCancer Research, 2013
- Inhibition of transforming growth factor-β release from tumor cells reduces their motility associated with epithelial-mesenchymal transitionOncology Reports, 2013
- Transforming Growth Factor-β1 (TGF-β1)-stimulated Fibroblast to Myofibroblast Differentiation Is Mediated by Hyaluronan (HA)-facilitated Epidermal Growth Factor Receptor (EGFR) and CD44 Co-localization in Lipid RaftsOnline Journal of Public Health Informatics, 2013
- FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.Anti-Cancer Agents in Medicinal Chemistry, 2013
- Transforming growth factor-β1 treatment of oral cancer induces epithelial-mesenchymal transition and promotes bone invasion via enhanced activity of osteoclastsClinical & Experimental Metastasis, 2013
- Efficient TGFβ-induced epithelial–mesenchymal transition depends on hyaluronan synthase HAS2Oncogene, 2012
- TGFβ and EGF synergistically induce a more invasive phenotype of epithelial ovarian cancer cellsBiochemical and Biophysical Research Communications, 2010